A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
- PMID: 9796041
- DOI: 10.1016/s0264-410x(98)00226-6
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
Abstract
In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to Bordetella pertussis infection were higher (p < 0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of < 7 EU ml-1 had a 67% (18/27) chance of infection regardless of the PT value. If the pertactin value was > or = 7 EU ml-1 and the PT value > or = 66 EU ml-1 all subjects were non-cases. If the pertactin value was > or = 7 and the PT value was < 66 EU ml-1 the predicted probability of being a case was 31% (15/49). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or PT/FHA vaccines.
Comment in
-
Serological correlates of immunity to Bordetella pertussis.Vaccine. 1998 Dec;16(20):1899-900. doi: 10.1016/s0264-410x(98)00228-x. Vaccine. 1998. PMID: 9796040 No abstract available.
Similar articles
-
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.Vaccine. 1998 Dec;16(20):1907-16. doi: 10.1016/s0264-410x(98)00227-8. Vaccine. 1998. PMID: 9796042 Clinical Trial.
-
Comparison of 13 acellular pertussis vaccines: overview and serologic response.Pediatrics. 1995 Sep;96(3 Pt 2):548-57. Pediatrics. 1995. PMID: 7659475 Clinical Trial.
-
Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.Pediatrics. 2001 Nov;108(5):E81. doi: 10.1542/peds.108.5.e81. Pediatrics. 2001. PMID: 11694665 Clinical Trial.
-
How to make sense of pertussis immunogenicity data.Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S288-91. doi: 10.1086/322564. Clin Infect Dis. 2001. PMID: 11709761 Review.
-
Acellular pertussis vaccines and the role of pertactin and fimbriae.Expert Rev Vaccines. 2007 Feb;6(1):47-56. doi: 10.1586/14760584.6.1.47. Expert Rev Vaccines. 2007. PMID: 17280478 Review.
Cited by
-
Screening of Novel Drug Targets and Drug Design for Bordetella pertussis: A Subtractive Proteomics Approach.Curr Res Microb Sci. 2024 Oct 19;7:100291. doi: 10.1016/j.crmicr.2024.100291. eCollection 2024. Curr Res Microb Sci. 2024. PMID: 39497932 Free PMC article.
-
Structural Basis for Antibody Neutralization of Pertussis Toxin.bioRxiv [Preprint]. 2024 Sep 23:2024.09.23.614357. doi: 10.1101/2024.09.23.614357. bioRxiv. 2024. PMID: 39386618 Free PMC article. Preprint.
-
Maternal Pertussis Immunization and Immunoglobulin G Levels in Early- to Late-Term and Preterm Infants.JAMA Netw Open. 2024 Jul 1;7(7):e2424608. doi: 10.1001/jamanetworkopen.2024.24608. JAMA Netw Open. 2024. PMID: 39078627 Free PMC article.
-
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis.Nat Commun. 2024 Mar 8;15(1):2133. doi: 10.1038/s41467-024-46560-w. Nat Commun. 2024. PMID: 38459022 Free PMC article.
-
Comparative Evaluation of Recombinant and Acellular Pertussis Vaccines in a Murine Model.Vaccines (Basel). 2024 Jan 22;12(1):108. doi: 10.3390/vaccines12010108. Vaccines (Basel). 2024. PMID: 38276680 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical